RCM
SPRO icon

Raleigh Capital Management’s Spero Therapeutics SPRO Stock Holding History

Raleigh Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500
Closed -$860 – 1015
2024
Q1 		$860 Buy
+500
New +$784 ﹤0.01% 855

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raleigh Capital Management's SPRO Position: Q2 2024 in Review

Raleigh Capital Management sold out of Spero Therapeutics (SPRO) in Q2 2024, closing a stake of 500 shares — an estimated $860 sold.

Raleigh Capital Management first reported a position in SPRO in Q1 2024 and held it in 1 quarter. The position peaked at $860 in Q1 2024. 48 funds tracked by Wall St. Rank hold SPRO as of Q2 2024.

  • Raleigh Capital Management reported no remaining Spero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 500 Spero Therapeutics shares in Q2 2024, an estimated $860.
  • Raleigh Capital Management first reported a position in Spero Therapeutics in Q1 2024 and held it in 1 quarter.
  • Raleigh Capital Management's Spero Therapeutics position peaked at $860 in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2024.

Based on Raleigh Capital Management's 13F filing for Q2 2024, filed 31 Jul 2024.